Hepatopulmonary Syndrome and Portopulmonary Hypertension in the Same Patient

Case Report

Abbreviations

HPS: Hepatopulmonary Syndrome; POPH: Portopulmonary Hypertension; RHC: Right Heart Catheterization; PAPm: Pulmonary Arterial Pressure

Introduction

Association of chronic liver disease with respiratory symptoms and hypoxia is well recognized, owing to the success of liver transplantation, there has been increasing the importance of recognition of pulmonary vascular complications of hepatic disease states [1]. Hepatopulmonary syndrome (HPS) and portopulmonary hypertension (POPH) are relatively common complications in patients among liver transplantation candidates [2]. HPS and POPH can share similar respiratory symptoms, though the physiology is different and both are considered mutually exclusive.

Pathophysiology of these two entities could be related with an imbalance between vasoconstrictor and vasodilator [3]. Angiogenic factors that escape from hepatic metabolism could play a role in the pulmonary circulation through collateral shunts and the pathogenesis of POPH [4]. HPS has been defined as an oxygenation defect caused by development of intrapulmonary vascular dilatation in patients with either advanced liver disease and/or portal hypertension [5]. While POPH is characterized by an increase in the pulmonary vascular resistance as a consequence of obstruction to pulmonary arterial blood flow with or without advanced liver disease [6], the main feature of HPS is vasodilatation.

The role of liver transplantation in reversing these vascular disorders is controversial, although complete resolution of HPS and, less frequently, POPH after liver transplantation has been reported [7].

Case Presentation

A 71-year-old woman with alcoholic cirrhosis presented to the emergency room and referred effort dyspnea for the last six months. She had a past medical history of ex-smoker (10 pack/year), glaucoma and hypothyroidism. She had been abstinent from alcohol for one year and showed no admissions for edematous-ascites syndrome, esophageal varices or spontaneous bacterial peritonitis. Her Model for End-Stage Liver Disease (MELD) score at the time of presentation to our center was 17.

On physical exam, her breath sounds were clear and did not show signs of fluid overload. Cyanosis, clubbing or platypnea were not present, however orthodeoxia was detected: SaO2 of 93% (0.21) in supine position and SaO2 of 89% in upright position. Computer tomography scans showed ground glass areas with and thickening of interlobular septa. Laboratory evaluation showed: hematocrit = 41%, hemoglobin = 14.5 g/dl, platelet count = 83000/mm3, total bilirubin = 2.7 g/dl, alkaline phosphatase = 118 U/l, serum albumine = 4.1 g/dl, aspartate aminotransferase = 30UI/l and alanine aminotransferase = 43UI/l. HIV serology was negative and her immunological profile inconsistent with collagen diseases.

Pulmonary function, respiratory gas exchange and ventilation-perfusion relationships were studied. Both forced spirometry results and lung volumes by plethysmography were normal. A severely reduced DLCO (37%) after adequate correction for anaemia was detected (Table 1).

Arterial blood gas (ABG) on room air revealed a pH of 7.43, partial pressure of oxygen (PaO2) was 57.7 mmHg, partial pressure of dioxide (PaCO2) was 30 mmHg, and an alveolar arterial gradient of 43 mmHg. Contrast enhanced transesophageal echocardiography

(cTEE) revealed extra cardiac shunt (Figure 1). Shunt calculated was 18%. The RHC showed a mean pulmonary arterial pressure (MPAP) of 28 mmHg and a pulmonary capillary wedge pressure (PCWP) of 11 mmHg.

During this hospitalization, we did not measure vascular resistance or cardiac output, so we decided to perform this study when the patient was discharged. The patient was stable during the 10 day hospital stay and then discharged with oxygen-therapy. Three months later, a new contrast enhanced TEE was performed and the pulmonary systolic pressure increased to 66 mmHg. Right Heart Catheterization (RHC) showed as mean pulmonary arterial pressure (PAPm) of 50 mmHg, wedge pressure of 13 mmHg, pulmonary vascular resistance (PVR) of 789 dyns/seg/cm² and a cardiac index of 3.75 l/min/m². This evidence supported the diagnosis of severe portopulmonary hypertension.

Lung perfusion scan with 99mTc macro-aggregated albumin showed low probability of pulmonary thromboembolism (Figure 2).

She began treatment with sildenafil (25 mg each 8 hours), but stopped it on the 4th day for headaches, flushing and increase of dyspnea. For this reason, she began treatment with ambrisentan 5 mg/daily, transaminases and arterial pressure levels did not increase and did clinically well.

This patient is assisted as an outpatient and is stable from hepatic dysfunction and dyspnea. Currently, she is waiting for new evaluation by liver transplant.

**Discussion**

Patients with HPS and POPH are rarely reported [8]. The first case was reported in 1999 by Martinez-Pall and coworkers [9]. Recently, Zopey and coworkers described a series of three non-transplanted patients: one of them improved with ambrisentan (similar treatment to our patient) and was added to the hepatic transplant waiting list [10].

HPS is characterized by hypoxemia, vascular pulmonary dilatation and hepatic disease1. Prevalence of HPS in patients on liver transplant waiting list is estimated at 20%. The main symptom is effort dyspnea, usually with a history of alcoholic cirrhosis. Patients with HPS show normal spirometry with moderate to severe decrease of DLCO. Classification is performed using oxemia levels: mild is defined as PaO2 > 80mmHg, moderate as 80-60mmHg, severe as 50-60 mmHg and very severe as < 50 mmHg [11]. Patients presented in this case had a severe HPS pattern. She got hepatic transplant criteria except for MELD. The complementary method recommended to detect pulmonary vascular dilatation is contrast-enhanced TTE (CE-TTE) and lung perfusion scan with Tc99 (Tecnecio 99) [12].

Liver transplant is recommended for HPS patients with hypoxemia (PaO2 between 60-50 mmHg), but not for patients with PaO2 < 50 mmHg because of proven poor results in these cases.

POPH is defined as pulmonary hypertension associated with portal hypertension whether or not portal hypertension is secondary to hepatic disease. Diagnosis is based on the pressure obtained by a RHC with MPAP > 25mmHg, pulmonary arterial occlusion pressure

<table>
<thead>
<tr>
<th>Table 1: Characteristics of pulmonary function, respiratory gas exchange and ventilation-perfusion relationships.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FVC (% predicted)</strong></td>
</tr>
<tr>
<td><strong>FEV1(% predicted)</strong></td>
</tr>
<tr>
<td><strong>FEV1/FVC</strong></td>
</tr>
<tr>
<td><strong>TLC liters</strong></td>
</tr>
<tr>
<td><strong>DLCO ml/min/mmHg(% predicted)</strong></td>
</tr>
<tr>
<td><strong>DLCO cor ml/min/mmHg</strong></td>
</tr>
<tr>
<td><strong>PaO2 mmHg (room air)</strong></td>
</tr>
<tr>
<td><strong>PaCO2 mmHg</strong></td>
</tr>
<tr>
<td><strong>PaO2 mmHg (100% O2)</strong></td>
</tr>
<tr>
<td><strong>Shunt</strong></td>
</tr>
</tbody>
</table>

**Abbreviations:** FEVr: Forced Expiratory Volume at 1 s; FVC: Forced Vital Capacity; TLC: Total Lung Capacity; DLco. Single-breath carbon monoxide diffusing capacity; PaO2: arterial PO2; PaCO2: arterial PCO2 Shunt: percentage of blood flow to unventilated units.
of (PAOP) < 15 mmHg and an increase in pulmonary vascular resistance of (PVR) > 240 dynes/seg/cm-5. POPH is classified as mild (mPAP >25<35mmHg), mild to moderate (mPAP 35-45mmHg) and severe (MPAP > 45mmHg). The estimated prevalence reported is variable, between 2.5% and 8.5%, in patients on liver transplant list [13].

Physiology of PPOH is characterized by vascular alteration that leads to increased vasoconstriction and remodeling of pulmonary arterial bed including small vases vessels. Symptoms usually have insidious onset and are nonspecific. Patients refer effort and rest dyspnea and show signs of right heart failure. Screening is performed with cTEE which has shown high sensitivity but low specificity. Systolic pressure of left ventricle (SPLV) < 30 mmHg could contribute to rule out HPS, however SPLV > 50 mmHg is used to confirm moderate to severe HPS. A SPLV < 38 mmHg has recently been proposed to limit the number of false positives. Lung perfusion scan and High Resolution Computed Tomography with contrast and thin slides could confirm pulmonary thromboembolism. Lung catheterization is required to define diagnosis [14]. Conventional treatment consists of fluid overload with diuretics and oxygen but does not improve survival rate [15]. Inhibitors of 1-endothelin as bosentan are an effective treatment in stable hepatic illness, however there is insufficient evidence of its effectiveness in patients with altered hepatic dysfunction [16]. Furthermore, patients treated with bosentan have shown better results in hemodynamic parameters and the 6 minute-walk distance test (6MWD) compared with patients treated with inhaled iloprost [17]. It has been demonstrated that treatment with ambrisentan has less hepatic toxicity and improves hemodynamic parameters with respect to bosentan [18]. Patients with HSP could be treated with inhaled iloprost, which improves 6MWD and the hepatic function. Sildenafil is the best option to improve POPH because it maintains hemodynamic parameters [19].

References


